Literature DB >> 10903900

Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein.

S Takahashi1, H Wakui, J A Gustafsson, J Zilliacus, H Itoh.   

Abstract

Mizoribine (MIZ) is a novel imidazole nucleoside with immunosuppressive activity. MIZ has been approved in Japan and combination therapy with MIZ and glucocorticoids has been used after renal transplantation and for lupus nephritis and rheumatoid arthritis. In this study, we identify 14-3-3 proteins as MIZ-binding proteins. 14-3-3 proteins interact with many proteins involved in cellular signaling, including the glucocorticoid receptor (GR). The 14-3-3/GR interaction enhances the transcriptional activity of the receptor. We show that MIZ affects the conformation of 14-3-3 proteins and enhances the interaction of GR and 14-3-3eta dose dependently in vitro. MIZ also has a stimulatory effect on transcriptional activation by the GR. Our results point to the possibility that one mechanism for the therapeutic effect of MIZ could be to regulate the GR function via 14-3-3 proteins. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903900     DOI: 10.1006/bbrc.2000.3104

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  33 in total

Review 1.  Metabolic enzymes as targets for 14-3-3 proteins.

Authors:  Steven C Huber; Carol MacKintosh; Werner M Kaiser
Journal:  Plant Mol Biol       Date:  2002-12       Impact factor: 4.076

Review 2.  Functional specificity in 14-3-3 isoform interactions through dimer formation and phosphorylation. Chromosome location of mammalian isoforms and variants.

Authors:  Alastair Aitken
Journal:  Plant Mol Biol       Date:  2002-12       Impact factor: 4.076

Review 3.  Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes.

Authors:  Carol Mackintosh
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

4.  Effectiveness of cryofiltration and mizoribine combination with oral steroid therapy in a patient with membranoproliferative glomerulonephritis due to essential cryoglobulinemia.

Authors:  Yuka Kurokawa; Kiyomi Koike; Yusuke Kaida; Sakuya Ito; Hirotane Chiba; Kengo Urae; Tomofumi Moriyama; Nao Nakamura; Tetsurou Imai; Ryo Shibata; Takuma Hazama; Daisuke Wakasugi; Seiya Okuda; Kei Fukami
Journal:  CEN Case Rep       Date:  2019-03-29

5.  Mizoribine-induced severe hyperglycemia in a patient with microscopic polyangiitis.

Authors:  Ryo Ishida; Kazumi Komaki; Tsuneyuki Nakanouchi; Tetsuro Kusaba
Journal:  CEN Case Rep       Date:  2013-09-26

6.  Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial.

Authors:  Kosuke Masutani; Akihiro Tsuchimoto; Tomomi Yamada; Makoto Hirakawa; Koji Mitsuiki; Ritsuko Katafuchi; Hideki Hirakata; Takanari Kitazono; Kazuhiko Tsuruya
Journal:  Clin Exp Nephrol       Date:  2016-01-13       Impact factor: 2.801

7.  The first year results of mizoribine/tacrolimus-based multitarget treatment for consecutive patients with lupus nephritis.

Authors:  Hidetoshi Kagawa; Tsutomu Hiromasa; Ryutaro Yamanaka; Reika Hayashi; Yoko Tsunashima; Tatsuyuki Inoue; Ken-Ei Sada
Journal:  Clin Exp Nephrol       Date:  2018-06-09       Impact factor: 2.801

Review 8.  Mizoribine in the treatment of pediatric-onset glomerular disease.

Authors:  Hiroshi Tanaka; Kazushi Tsuruga; Taddatsu Imaizumi
Journal:  World J Pediatr       Date:  2015-03-09       Impact factor: 2.764

9.  Maintenance treatment using the purine-synthesis inhibitor mizoribine in a patient with relapsing thrombotic thrombocytopenic purpura.

Authors:  Tetsuya Kawamura; Joichi Usui; Kei Nagai; Kentaro Sakai; Itaru Ebihara; Kunihiro Yamagata
Journal:  CEN Case Rep       Date:  2017-11-09

Review 10.  Mizoribine: a new approach in the treatment of renal disease.

Authors:  Yukihiko Kawasaki
Journal:  Clin Dev Immunol       Date:  2009-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.